Latest
- Congratulations to Dr. Deleu
- Extracellular RNA in liquid biopsies: entering a new era for cancer treatment monitoring?
- Longitudinal evaluation of serum microRNAs as biomarkers for neuroblastoma burden and therapeutic p53 reactivation
- Digital PCR-based evaluation of nucleic acid extraction kit performance for the co-purification of cell-free DNA and RNA
- Performance evaluation of RNA purification kits and blood collection tubes in the Extracellular RNA Quality Control (exRNAQC) study
- Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA
- Cost-effective and robust genotyping using double-mismatch allele-specific quantitative PCR
- Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients
- MicroRNA Expression Analysis Using Small RNA Sequencing Discovery and RT-qPCR-Based Validation
- Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma
- Depletion of tRNA-halves enables effective small RNA sequencing of low-input murine serum samples
- Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma
- Identification of miRNAs contributing to neuroblastoma chemoresistance
- Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma
- CASP8 SNP D302H (rs1045485) Is Associated with Worse Survival in MYCN-Amplified Neuroblastoma Patients
- Characterization of the p53 network and new therapeutic opportunities in neuroblastoma
- Lack of association betweenMDM2promoter SNP309 and clinical outcome in patients with neuroblastoma
- Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer
- Effective Alu Repeat Based RT-Qpcr Normalization in Cancer Cell Perturbation Experiments
- Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes
- Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
- EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells
- New options for molecular therapy of neuroblastoma: from p53 to gene therapy
- Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53
- The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy